WB-308

Overview

WB-308 is a novel small molecule that was identified as an inhibitor of EGFR by an in vitro EGFR kinase activity system. WB-308 was able to reduce the proliferation and clonogenicity of NSCLC cells, causing G2/M phase arrest and apoptosis . In addition, WB-308 inhibited tumor growth in two in vivo animal models (lung orthotopic transplantation model and patient-derived clonal mouse model). WB-308 impaired the phosphorylation of EGFR , AKT , and ERK1/2 proteins. Compared with Gefitinib, WB-308 had lower cytotoxicity. This study showed that WB-308 is a new EGFR-TKI that may be considered as an alternative to Gefitinib in the clinical treatment of NSCLC.

Application

Products | Products > Signaling Pathways > JAK/STAT Signaling | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > Stem Cell/Wnt | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > ERK | Products > Signaling Pathways > Akt | Products > Signaling Pathways > EGFR | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-116504
• CAS No.: 1373764-87-4
• Molecular Formula: C19H17FN2O
• Molecular Weight: 308.35
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source